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Pressure ulcers represent a significant cause of
morbidity and health care expenditure in the United
States. A pressure ulcer is a lesion of localized injury
to the skin or underlying tissue, usually over a bony
prominence, resulting from pressure alone or in
combination with shear forces.1 Ulcers are staged
based on depth of tissue involvement. Using the
revised National Pressure Ulcer Advisory Panel
Staging System, a stage IV pressure ulcer is
characterized by full-thickness tissue loss with
exposed bone, tendon, or muscle that is visible or
directly palpable.1
In recent years, there has been growing interest in
the use of bioengineered skin substitutes for the
treatment of chronic wounds such as pressure ulcers.
Onesuchproduct,OASISUltraTri-LayerWoundMatrix
(Smith & Nephew, Inc, Hull, UK), is a dermal skin
substitute derived from decellularized porcine jejunal
submucosa.2 We present a case of impressive wound
healing using OASIS Ultra Tri-LayerWoundMatrix in a
patient with multiple stage IV pressure ulcers.
CASE REPORT
A 41-year-old woman with T9 paraplegia pre-
sented to the emergency department in March 2014
with fever and chronic pressure ulcers of the sacrum
and vulva caused by an ill-fitting wheelchair. She had
a history of a sacral pressure ulcer since 2012 with
associated coccygeal osteomyelitis (Fig 1, A). She
was treated previously with wound vacuum
dressings and Apligraf (Organogenesis, Inc,
Canton, MA), a bilayer living tissue matrix, by an
outside wound care facility.
Laboratory results showed leukocytosis, anemia,
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osteomyelitis involving the right pubic ramus and
hip joint. The patient was evaluated by the plastic
surgery department and determined to be a poor
candidate for surgical intervention because of her
poor nutritional status and current smoking. Based
on wound culture results, she was started on
intravenous ertapenem via peripherally inserted
central catheter for osteomyelitis and recommended
for outpatient wound care follow-up.
The patient presented to the wound care clinic in
March 2014. Examination found a sacral wound with
tunneling to 3 cm and granulation tissue noted in
the wound bed (Fig 1, A). Over time, this ulcer
degenerated to a stage IV ulcer with exposed muscle
at the base.
Two weeks later, the patient had a left greater
trochanter ulcer (Fig 2, A). The wound had a large,
black eschar and necrotic tissue in the wound bed.
The ulcer continued to collapse and was debrided.
Ultimately, the ulcer extended to the joint capsule.
In May 2014, examination found a new sacral
ulcer distal to her initial ulcer, with a large amount of
necrotic tissue in the wound (Fig 3, A). The ulcer
progressed until there was tunneling with palpable
bone at the base of the wound. Thus, the patient’s
presentation was consistent with a diagnosis of
multiple stage IV pressure ulcers.
Initially, wound care therapy was directed at
limiting infection, controlling malodor, and
providing palliative care. Treatment was compli-
cated by Pseudomonas aeruginosa infection, which
was treated with ciprofloxacin. In June 2014, weekly
debridement of all 3 was instituted. Multidisciplinary
care included consultations from the departments of
infectious disease, orthopedic surgery, gynecology,JAAD Case Reports 2016;2:122-4.
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Fig 1. Stage IV pressure ulcer of the proximal sacrum, before (A) and after (B) treatment.
Fig 2. Stage IV pressure ulcer of left greater trochanter, before (A) and after (B) treatment.
Fig 3. Stage IV pressure ulcer of the distal sacrum, before (A) and after (B) treatment.
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were available. The patient was placed on nutritional
supplementation.
Together with the patient, we decided to attempt
more aggressive treatment of the sacral pressure
ulcers and the left trochanteric ulcer. Treatment with
OASIS Ultra Tri-Layer Wound Matrix was initiated in
August 2014. OASIS was applied to the wounds
weekly, with the exception of a single 1-week
postponement in application. OASIS therapy wascoupledwith strict bed rest and continued nutritional
supplementation.
By week 5 of OASIS application, significant
improvement was noted. By week 11 of OASIS
therapy, thin scar tissue had formed over the left
greater trochanter and both sacral ulcers. The patient
was advised to avoid sitting for more than 2 hours to
prevent tissue breakdown.
The ulcers have maintained durable healing to
date, as of April 2015. The initial sacral wound healed
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2 wounds healed with 11 OASIS applications (Figs 2,
B and 3, B).DISCUSSION
Pressure ulcer therapy is directed at eliminating
external pressure, preserving surrounding tissue,
debriding necrotic tissue, reducing bacterial load,
relieving pain, and treating conditions such as
malnutrition and anemia that impede healing and
increase risk for further ulcers.3 Even with ideal
treatment, however, only 30% of stage IV pressure
ulcers resolve within 6 months.4 Surgical debride-
ment and flap reconstruction are frequently
used; however, recurrence is a problem, and
autologous grafts also pose a challenge when donor
sites are involved or unable to provide enough
tissue.2,4
The dramatic improvement observed in our
patient suggests that OASIS Ultra Tri-Layer Wound
Matrix may represent a promising therapy for wound
closure in stage IV pressure ulcers. Dermal
substitutes such as OASIS provide wound coverage,
precluding bacteria, and behave similarly to the
skin’s native extracellular matrix, providing
scaffolding for the influx of bioactive molecules
that disrupt the proinflammatory milieu of chronic
wounds.5
To date, effective wound healing using OASIS has
been shown primarily in chronic leg ulcers. Mostow
et al6 found significantly increased healing of chronic
venous leg ulcers in patients receiving OASIS
plus compression therapy compared with patients
receiving compression therapy alone. A second
study found that OASIS was superior to petroleum-
embedded dressings in the treatment of leg ulcers of
mixed arterial/venous etiologies.7Currently, OASIS Wound Matrix is indicated for
use in partial and full-thickness wounds, including
pressure ulcers, chronic vascular ulcers, diabetic
ulcers, trauma wounds, and surgical wounds.
Treatment with OASIS offers advantages over other
dermal substitutes in that it is readily available,
inexpensive, and has a relatively long shelf life
(2 years at room temperature).2
There is no consensus on the ideal dressing to
treat stage IV pressure ulcers; most clinical trials are
small and have conflicting data.8 Given the variety
of dressings available, more clinical trials are
needed. However, our patient showed impressive
improvement with OASIS treatment. We propose
that OASIS Wound Matrix be considered as first-line
therapy for stage IV pressure ulcers.
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